{"id":388128,"date":"2020-11-24T16:33:07","date_gmt":"2020-11-24T21:33:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388128"},"modified":"2020-11-24T16:33:07","modified_gmt":"2020-11-24T21:33:07","slug":"vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/","title":{"rendered":"vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital"},"content":{"rendered":"
\n

HIGH POINT, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc.<\/a>\u00a0(Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (\u201cPurchase Agreement<\/u>\u201d) for up to $47 million with Lincoln Park Capital Fund, LLC (\u201cLPC<\/u>\u201d), a Chicago-based institutional investor.<\/p>\n

\u201cThe LPC financing will help us reach a number of potential value-driving events over the next six to nine months, including the upcoming topline results of our phase 2 Elevage Study in patients with Alzheimer\u2019s disease and type 2 diabetes in December,\u201d said Steve Holcombe, President and CEO of vTv Therapeutics. \u201cIn addition, these funds will help us conduct a mechanistic study of TTP399, our oral treatment for patients with type 1 diabetes focused on its impact on diabetic ketoacidosis, and additionally a multiple-ascending dose study of HPP737 as a potential oral treatment for psoriasis.\u201d<\/p>\n

vTv will have the option, but not the obligation, to sell to LPC up to $47.0 million in shares of Class A common stock over a thirty-six-month period subject to certain conditions, including a registration statement being filed and declared effective by the SEC. There are no upper limits to the price LPC may pay to purchase Class A common stock from vTv and the purchase price of the shares will be based on the prevailing market prices of vTv\u2019s shares at the time of each sale to LPC.<\/p>\n

LPC has agreed not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of vTv\u2019s shares of Class A common stock. No warrants, derivatives, or other share classes are associated with this agreement. In consideration for entering into the agreement, vTv has issued shares of Class A common stock to LPC as a commitment fee. The Purchase Agreement may be terminated by vTv at any time, at its sole discretion, without any additional cost or penalty.<\/p>\n

vTv intends to use the net proceeds from the transaction for general corporate purposes and to support its clinical development strategy, including finalizing and reporting topline results from the Company\u2019s ongoing Elevage Study of azeliragon for the treatment of Alzheimer\u2019s disease in patients with type 2 diabetes in December 2020, conducting a mechanistic study of TTP399 in patients with type 1 diabetes, and conducting a multiple-ascending dose study of HPP737 as part of a development program of the product as an oral therapy for psoriasis.<\/p>\n

A more detailed description of the agreement is set forth in vTv\u2019s Current Report on Form 8-K to be filed with the SEC.<\/p>\n

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.<\/p>\n

\n About vTv Therapeutics<\/strong>
\n
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimer\u2019s disease, and psoriasis. vTv\u2019s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), and genetic mitochondrial diseases. For more information, please visit www.vtvtherapeutics.com<\/a> or follow us on Twitter: @vTvTherapeutics.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading \u201cRisk Factors\u201d in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n

Investors:<\/p>\n

Corey Davis
LifeSci Advisors
CDavis@LifeSciAdvisors.com<\/a><\/p>\n

or<\/p>\n

Media:<\/p>\n

Glenn Silver
Lazar FINN Partners
646-871-8485
gsilver@lazarpartners.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HIGH POINT, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc.\u00a0(Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (\u201cPurchase Agreement\u201d) for up to $47 million with Lincoln Park Capital Fund, LLC (\u201cLPC\u201d), a Chicago-based institutional investor. \u201cThe LPC financing will help us reach a number of potential value-driving events over the next six to nine months, including the upcoming topline results of our phase 2 Elevage Study in patients with Alzheimer\u2019s disease and type 2 diabetes in December,\u201d said Steve Holcombe, President and CEO of vTv Therapeutics. \u201cIn addition, these funds will help us conduct a mechanistic study of TTP399, our oral treatment for patients with type 1 diabetes focused on its impact on … <\/p>\n

Continue reading “vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388128","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nvTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HIGH POINT, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc.\u00a0(Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (\u201cPurchase Agreement\u201d) for up to $47 million with Lincoln Park Capital Fund, LLC (\u201cLPC\u201d), a Chicago-based institutional investor. \u201cThe LPC financing will help us reach a number of potential value-driving events over the next six to nine months, including the upcoming topline results of our phase 2 Elevage Study in patients with Alzheimer\u2019s disease and type 2 diabetes in December,\u201d said Steve Holcombe, President and CEO of vTv Therapeutics. \u201cIn addition, these funds will help us conduct a mechanistic study of TTP399, our oral treatment for patients with type 1 diabetes focused on its impact on … Continue reading "vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T21:33:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTg2MyMzODQyOTY4IzIwMTk3OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital\",\"datePublished\":\"2020-11-24T21:33:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\\\/\"},\"wordCount\":889,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTg2MyMzODQyOTY4IzIwMTk3OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\\\/\",\"name\":\"vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTg2MyMzODQyOTY4IzIwMTk3OTU=\",\"datePublished\":\"2020-11-24T21:33:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTg2MyMzODQyOTY4IzIwMTk3OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTg2MyMzODQyOTY4IzIwMTk3OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/","og_locale":"en_US","og_type":"article","og_title":"vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital - Market Newsdesk","og_description":"HIGH POINT, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc.\u00a0(Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (\u201cPurchase Agreement\u201d) for up to $47 million with Lincoln Park Capital Fund, LLC (\u201cLPC\u201d), a Chicago-based institutional investor. \u201cThe LPC financing will help us reach a number of potential value-driving events over the next six to nine months, including the upcoming topline results of our phase 2 Elevage Study in patients with Alzheimer\u2019s disease and type 2 diabetes in December,\u201d said Steve Holcombe, President and CEO of vTv Therapeutics. \u201cIn addition, these funds will help us conduct a mechanistic study of TTP399, our oral treatment for patients with type 1 diabetes focused on its impact on … Continue reading \"vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T21:33:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTg2MyMzODQyOTY4IzIwMTk3OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital","datePublished":"2020-11-24T21:33:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/"},"wordCount":889,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTg2MyMzODQyOTY4IzIwMTk3OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/","name":"vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTg2MyMzODQyOTY4IzIwMTk3OTU=","datePublished":"2020-11-24T21:33:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTg2MyMzODQyOTY4IzIwMTk3OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTg2MyMzODQyOTY4IzIwMTk3OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-lincoln-park-capital\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388128"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388128\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}